Recommended Medications and Procedural Steps for PCI
For patients undergoing PCI, administer intravenous unfractionated heparin (UFH) 70-100 U/kg to achieve an ACT of 250-300 seconds, combined with aspirin (150-300 mg oral or 75-250 mg IV if not pre-treated) and a P2Y12 inhibitor loading dose (clopidogrel 600 mg for elective PCI, or prasugrel/ticagrelor for ACS), with consideration of GP IIb/IIIa inhibitors for high-risk situations. 1, 2
Anticoagulation During PCI
Primary Anticoagulant Choice
UFH remains the standard anticoagulant for PCI procedures 1, 2:
- Dosing: 70-100 U/kg bolus to achieve target ACT 250-300 seconds 1
- If patient received prior anticoagulation, give additional UFH as needed to reach target ACT 1
Alternative Anticoagulants
Bivalirudin is a useful alternative with specific advantages 1:
- For STEMI: Reduces mortality and bleeding compared to UFH (Class I, Level B-R) 1
- For NSTE-ACS: May reduce bleeding (Class IIb, Level B-R) 1
- Dosing: 0.75 mg/kg bolus, then 1.75 mg/kg/h IV infusion during procedure 1
- Post-PCI infusion for primary PCI: Continue 1.75 mg/kg/h for 2-4 hours 1
- Renal adjustment: Reduce to 1 mg/kg/h if CrCl <30 mL/min 1
Enoxaparin may be considered as an alternative 1, 2:
- Dosing for PCI support: 0.5-0.75 mg/kg IV bolus if no prior anticoagulation 1
- If last subcutaneous dose was 8-12 hours prior: give 0.3 mg IV 1
- If last dose within 8 hours: no additional dose needed 1
Critical caveat: Fondaparinux should NOT be used to support PCI due to catheter thrombosis risk (Class III Harm) 1
Antiplatelet Therapy
Pre-Procedural Loading
- Loading dose: 150-300 mg oral OR 75-250 mg IV if not pre-treated 2
- Essential before all PCI procedures 2
P2Y12 Inhibitor Selection depends on clinical presentation 2:
For Elective/Stable CAD:
- Clopidogrel 600 mg loading dose once coronary anatomy is known and PCI decision made (Class I, Level A) 2
- Pre-treatment may be considered if PCI probability is high (Class IIb) 2
For ACS/High-Risk Situations:
- Prasugrel or ticagrelor may be considered for specific high-risk scenarios (e.g., history of stent thrombosis, left main stenting) 2
Cangrelor may be considered in P2Y12-inhibitor naïve patients undergoing PCI (Class IIb, Level A) 2
GP IIb/IIIa Inhibitors
Use selectively 2:
- Should be considered only for bail-out situations in elective PCI (Class IIa, Level C) 2
- For ACS patients, particularly high-risk features: abciximab or eptifibatide recommended 1
Post-Procedural Management
Dual Antiplatelet Therapy (DAPT)
Standard duration: 6 months of clopidogrel plus aspirin after elective stenting, regardless of stent type (Class I, Level A) 2
Maintenance dosing 2:
- Clopidogrel: 75 mg daily
- Aspirin: 75-162 mg daily (lower doses 75-100 mg preferred when combined with other antithrombotics) 1
Extended DAPT considerations 2:
- For bioresorbable scaffolds: Consider at least 12 months
- Duration can be shortened (<6 months) or extended (>6-12 months) based on individual bleeding/ischemic risk
Long-Term Therapy
Life-long single antiplatelet therapy (usually aspirin) is recommended after DAPT completion (Class I, Level A) 2
Critical patient education: Instruct patients about the importance of compliance with antiplatelet therapy to prevent stent thrombosis and recurrent MI 2
Key Procedural Considerations
Anticoagulation Continuation
In patients with ACS undergoing revascularization (PCI or CABG) during the same admission, continue parenteral anticoagulation until revascularization to reduce complications (Class I, Level C-LD) 1
Post-Procedural Heparin
Do NOT routinely continue heparin infusion after uncomplicated PCI 1
Common Pitfalls to Avoid
- Never use fondaparinux to support PCI—high catheter thrombosis risk 1
- Do not prematurely discontinue antiplatelet therapy—risks stent thrombosis 2
- Adjust anticoagulant dosing for renal impairment, particularly with bivalirudin and enoxaparin 1
- Time enoxaparin supplementation correctly based on last subcutaneous dose 1